Journal
GROWTH HORMONE & IGF RESEARCH
Volume 17, Issue 5, Pages 431-434Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.ghir.2007.05.001
Keywords
growth hormone; receptor; pegvisomant; immunoassay; acromegaly; growth hormone binding protein
Categories
Ask authors/readers for more resources
Growth hormone (GH) and the GH receptor blocker, pegvisomant are usually circulating in high concentration in pegvisomant treated acromegalic patients. This and the close similarity between the peptides make determination of either difficult. In the present methodological study, endogenous GH in serum is initially isolated and determined in a slightly modified commercial immunometric assay, whereafter the now GH free medium allows measurement of pegvisomant. Inter-individual steady state levels of serum pegvisomant vary remarkably in both acromegalic patients and healthy controls, while the intra-individual variations are negligible. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available